dslevine Profile Banner
Daniel S. Levine Profile
Daniel S. Levine

@dslevine

Followers
2K
Following
180
Media
173
Statuses
3K

Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.

Berkeley, CA
Joined October 2009
Don't wanna be here? Send us removal request.
@dslevine
Daniel S. Levine
3 hours
Sunil Talathi of @BeOneMedicines sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company, prompt engineering, and the need for collaboration between humans and AI systems.
0
0
0
@dslevine
Daniel S. Levine
1 day
.@BioUsawa and @ServareGMP announced a strategic partnership to establish advanced monoclonal antibody manufacturing capabilities in Africa, directly addressing the critical healthcare access gap affecting patients in low- and middle-income countries.
Tweet card summary image
finance.yahoo.com
Strategic alliance brings advanced first-of-its-kind biotherapeutic production, workforce training, and rapid response capabilities to low- and middle-income countries to address healthcare equity...
0
0
0
@dslevine
Daniel S. Levine
6 days
Arun Upadhyay @Ocugen discusses inherited retinal diseases, the company’s gene therapies that can work across different genetic mutations, and the potential of its platform technology beyond the eye. @GlobalGenes #RARECast.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
8 days
Jenny Marlowe and Melissa Bonner of @nchromabio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies.
Tweet media one
0
1
0
@dslevine
Daniel S. Levine
13 days
Steve Mahoney @ViridianThera discusses thyroid eye disease, the challenges of living with the condition, and why its veligrotug has the potential to provide a new alternative for people living with the condition. @GlobalGenes #RARECast.
0
0
1
@dslevine
Daniel S. Levine
14 days
.@CraigLipset, advisor and founder of Clinical Innovation Partners, discusses how AI can bring greater predictability to clinical trials, how organizations can effectively adopt the technology, and the importance of fostering a culture of experimentation.
0
0
0
@dslevine
Daniel S. Levine
15 days
.@Niven_Narain , CEO of BPGbio discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
20 days
Traci Davies and her son Ben Davies both discuss their experiences with primary immunodeficiency, what it’s like to be both a caregiver and patient, and why they have both become patient advocates. @GlobalGenes #RARECast.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
22 days
.@PunitDhillon @skyebioscience discusses the limits of GLP-1 obesity therapies, the company’s experimental obesity therapy that works on a different target, and the potential to combine it with GLP-1 agonists and other therapeutic approaches.
Tweet media one
0
0
1
@dslevine
Daniel S. Levine
23 days
Bio Usawa and Bioeq AG announce a groundbreaking agreement to bring a life-changing biosimilar medicine—ranibizumab, used to treat serious retinal diseases—within reach for millions across Sub-Saharan Africa.
Tweet card summary image
globenewswire.com
Bio Usawa Biotechnology Ltd. and Bioeq AG today announced a partnership to bring a life-changing biosimilar of ranibizumab to Sub-Saharan Africa....
0
0
1
@dslevine
Daniel S. Levine
27 days
Melanie Kandzierski discusses how she has learned to care for a child with Dravet syndrome, care for herself, and to advocate not only for her child but others with complex medical conditions. @GlobalGenes #RARECast.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
28 days
Ariel Katz @H1co_ discusses the unique dataset behind the company’s platform to connect life sciences companies to healthcare providers, the problem it solves for biopharmaceutical companies, and some unexpected ways the platform has been used.
0
0
0
@dslevine
Daniel S. Levine
29 days
Steve Ruston, CEO of Persica Pharmaceuticals, discusses the need for new approaches to chronic low back pain, the company’s experimental targeted antibiotic injections, and the need to educate physicians about the role infection can play in the condition.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
1 month
Patrick Ritschel of Atsena Tx discusses the delivery challenges of gene therapies for inherited retinal diseases, how the company’s vector technology addresses this, and how it allows for safer and more effective delivery. @GlobalGenes #RARECast.
0
0
0
@dslevine
Daniel S. Levine
1 month
Barry Quart @ConnectBiopharm discusses the unmet need in asthma and COPD, the company’s experimental therapy rademikibart, and the case for a biologic that can address acute exacerbations of these conditions.
0
0
0
@dslevine
Daniel S. Levine
1 month
P.J. Brooks of @NIH @ncats_nih_gov discusses the treatment of an infant with a bespoke gene editing therapy, how researchers were able to move from diagnosis to treatment with speed, and what it would take to scale such an approach. @globalgenes #RARECast.
Tweet media one
0
0
0
@dslevine
Daniel S. Levine
1 month
Venky Iyer, director of data strategy and automation at @pfizer, discusses his journey in implementing AI solutions to enhance operational efficiency, the importance of managing change, and the value of AI adoption in improving drug development processes.
0
0
0
@dslevine
Daniel S. Levine
1 month
LeelandEkstrom of @NashvilleBio discusses its founding as a for-profit subsidiary of @VUMCDiscoveries, the significance its alliance with leading biopharmaceutical companies, and how it's enabling a transformation of drug development with data.
Tweet media one
0
0
1
@dslevine
Daniel S. Levine
2 months
Annette Bakker @ChildrensTumor discusses the complexities of neurofibromatosis, the foundation’s role in advancing research and drug development, and what other patient organizations can learn from its strategic approach.
0
0
1